Lenalidomida Stada 5 mg Hard Capsules EFG
Lenalidomida Stada 10 mg Hard Capsules EFG
Lenalidomida Stada 15 mg Hard Capsules EFG
Lenalidomida Stada 20 mg Hard Capsules EFG
Lenalidomida Stada 25 mg Hard Capsules EFG
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
-Keep this leaflet, as you may need to read it again.
-If you have any questions, ask your doctor or pharmacist.
-This medicine has been prescribed for you only. Do not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
1.What Lenalidomida Stada is and what it is used for
2.What you need to know before taking Lenalidomida Stada
3.How to take Lenalidomida Stada
4.Possible side effects
5.Storage of Lenalidomida Stada
6.Contents of the pack and additional information
What is Lenalidomida Stada
Lenalidomida Stada contains the active ingredient “lenalidomida”. This medicine belongs to a group of medicines that affect how the immune system works.
What Lenalidomida Stada is used for
Lenalidomida Stada is used in adults for:
Multiple myeloma
Multiple myeloma is a type of cancer that affects a specific type of white blood cell in the blood, called plasma cells. These cells accumulate in the bone marrow and multiply, becoming uncontrolled. This can damage bones and kidneys.
Multiple myeloma is usually incurable. However, the symptoms and signs can be significantly reduced or disappear for a period of time. This is called “remission”.
Newly diagnosed multiple myeloma:in patients who have undergone a bone marrow transplant
Lenalidomida is used as maintenance treatment after recovering adequately from a bone marrow transplant.
Newly diagnosed multiple myeloma: in patients who cannot be treated with a bone marrow transplant
Lenalidomida is taken with other medicines, including:
You will take these medicines when starting treatment and then continue taking lenalidomida alone.
If you are 75 years or older or have moderate to severe kidney problems, your doctor will closely monitor you before starting treatment.
Multiple myeloma: in previously treated patients
Lenalidomida is taken with an anti-inflammatory called “dexametasona”.
Lenalidomida can slow the progression of multiple myeloma symptoms. It has also been shown to delay the recurrence of multiple myeloma after treatment.
Myelodysplastic syndromes (MDS)
MDS are a group of many different blood and bone marrow diseases. Blood cells become abnormal and do not function correctly. Patients may experience a variety of symptoms, including low red blood cell count (anemia), the need for blood transfusions, and the risk of infection.
Lenalidomida is used to treat adult patients diagnosed with MDS, when the following points are applicable:
Lenalidomida can increase the number of healthy red blood cells produced by the body by reducing the number of abnormal cells:
Castleman's disease (LCD)
Castleman's disease is a cancer of a part of the immune system (lymphoid tissue). It affects a type of white blood cell in the blood called “B lymphocytes” or B cells. Castleman's disease is a disease in which B cells grow uncontrollably and accumulate in lymphoid tissue, bone marrow, or blood.
Lenalidomida is used in monotherapy to treat adult patients who have received previous treatment with other medicines.
Follicular lymphoma (FL)
FL is a slow-growing cancer that affects B lymphocytes. These are a type of white blood cell that helps the body fight infections. When a person has FL, they may store too many of these B lymphocytes in the blood, bone marrow, lymph nodes, and spleen.
Lenalidomida is used with another medicine called “rituximab” for the treatment of adult patients who have received previous treatment for follicular lymphoma.
How Lenalidomida Stada works
Lenalidomida works by affecting the body's immune system and directly attacking cancer. It acts in several ways:
.
Do not take Lenalidomida Stada:
If any of these conditions apply to you, do not take lenalidomide. In case of doubt, consult your doctor.
Warnings and precautions
Consult your doctor, pharmacist or nurse before starting to take Lenalidomida Stada if:
If any of the above alterations apply to you, inform your doctor, pharmacist or nurse before starting treatment.
At any time, during or after treatment, inform your doctor or nurse immediately if you experience:
Analysis and tests
Before starting treatment with lenalidomide and during the same, blood tests will be done regularly. This is because lenalidomide can cause a decrease in the blood cells that help fight infections (white blood cells) and those that participate in coagulation (platelets).
Your doctor will ask you to have a blood test:
You may be evaluated to detect signs of cardiopulmonary problems before and during treatment with lenalidomide.
For patients with SMD who take Lenalidomida Stada
If you have SMD, you may be more prone to developing a more advanced disease called acute myeloid leukemia (AML). In addition, it is unknown how lenalidomide affects the likelihood of developing AML. Your doctor may perform tests to detect signs that may better predict the likelihood of developing AML during treatment with lenalidomide.
For patients with LCM who take Lenalidomida Stada
Your doctor will ask you to have a blood test:
?before treatment;
?every week during the first 8 weeks (2 cycles) of treatment;
?after that, at the beginningof each cycle;
?at least once a month.
For patients with LF who take Lenalidomida Stada
Your doctor will ask you to have a blood test:
Your doctor may check if you have a high total tumor burden in the body, including the bone marrow. This could lead to a disease in which the tumors break down and produce unusual levels of chemical substances in the blood that, in turn, can cause kidney failure (this disease is called “tumor lysis syndrome”).
Your doctor may examine you to check if any changes have occurred in your skin, such as red spots or skin rashes.
Your doctor may adjust your lenalidomide dose or interrupt your treatment, depending on the results of your blood tests and your overall condition. If you are a new diagnosis patient, your doctor may also evaluate your treatment based on your age and any other conditions you already have.
Blood donation
You should not donate blood during treatment or for at least 7 days after the end of treatment.
Children and adolescents
The use of lenalidomide is not recommended in children and adolescents under 18 years old.
Older people and people with kidney problems
If you are 75 years old or more or have moderate to severe kidney problems, your doctor will examine you carefully before starting treatment.
Other medicines and Lenalidomida Stada
Inform your doctor or nurse if you are taking, have taken recently or may have to take any other medicine. This is because lenalidomide can affect how other medicines work. In addition, some medicines can affect how lenalidomide works.
Specifically, inform your doctor or nurse if you are taking any of the following medicines:
Pregnancy, breastfeeding and contraception: information for women and men
Pregnancy
Women taking Lenalidomida Stada
Men taking Lenalidomida Stada
Breastfeeding
You should not breastfeed while taking lenalidomide, as it is unknown whether lenalidomide passes into breast milk.
Contraception
For women taking Lenalidomida Stada
Before starting treatment, ask your doctor if you are capable of becoming pregnant, although you may think this is unlikely.
If you can become pregnant:
And
For men taking Lenalidomida Stada
Lenalidomide passes into human semen. If your partner is pregnant or may become pregnant and does not use any effective contraceptive method, you must use condoms during treatment and for at least 7 days after treatment ends, even if you have undergone a vasectomy. You should not donate semen or sperm during treatment or for at least 7 days after treatment ends.
Driving and using machines
You should not drive or use machines if you feel dizzy, tired, drowsy, have vertigo or blurred vision after taking lenalidomida.
Lenalidomida Stada contains lactose and sodium
LenalidomidaStada contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medicine.
This medicine contains less than 1 mmolof sodium (23 mg) per capsule; this is, essentially “sodium-free”.
Follow exactly the administration instructions of lenalidomide indicated by your doctor. In case of doubt, consult your doctor or pharmacist.
If you are taking lenalidomide with other medications, you must consult the leaflet of those other medications to obtain additional information on their use and effects.
Treatment Cycle
Lenalidomide is taken on certain days during the period of 3 weeks (21 days).
Or
Lenalidomide is taken on certain days during the period of 4 weeks (28 days).
How much Lenalidomide Stada to take
Before starting treatment, your doctor will indicate:
How and when to take Lenalidomide Stada
Medication intake
To remove the capsule from the blister:
Duration of treatment with Lenalidomide Stada
Lenalidomide is taken in treatment cycles, each cycle lasting 21 or 28 days (see “Treatment Cycle” above). You should continue the treatment cycles until your doctor informs you to stop treatment.
If you take more Lenalidomide Stada than you should
If you take more lenalidomide than prescribed, inform your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Lenalidomide Stada
If you forget to take lenalidomide at your usual time and:
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, lenalidomide can cause side effects, although not everyone will experience them.
If you experience any of the following serious side effects, stop taking lenalidomide and seek medical attention immediately, as it may require emergency medical treatment:
Seek immediate medical attention if you notice any of the following serious side effects:
Lenalidomide can reduce the number of white blood cells that fight infections and also reduce the number of blood cells that help to clot blood (platelets), which can cause bleeding disorders such as nosebleeds and bruises. Lenalidomide can also cause blood clots in the veins (thrombosis).
Other side effects
It is essential to note that a reduced number of patients may develop other types of cancer, and this risk may increase with lenalidomide treatment. Therefore, your doctor must carefully evaluate the benefits and risks of prescribing lenalidomide to you.
Side effectsvery common(may affect more than 1 in 10 people):
Side effectscommon(may affect up to 1 in 10 people):
Side effectsuncommon(may affect up to 1 in 100 people):
Side effects of unknown frequency(cannot be estimated from available data):
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and the box after “CAD”. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Do not use this medication if you observe visible signs of deterioration or signs of improper handling.
Medications should not be disposed of through drains or in the trash. Return unused medication to your pharmacist. This will help protect the environment.
Composition of Lenalidomida Stada
Lenalidomida Stada 5 mg hard capsules EFG:
-Fill of the capsules: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-Capsule coating: Brilliant Blue FCF (E133), iron oxide red (E172), iron oxide yellow (E172), titanium dioxide (E171) and gelatin.
-Printing ink: shellac, propylene glycol (E1520), iron oxide black (E172) and potassium hydroxide.
Lenalidomida Stada 10 mg hard capsules EFG:
-Fill of the capsules: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-Capsule coating: iron oxide black (E172), iron oxide yellow (E172), titanium dioxide (E171) and gelatin.
-Printing ink: shellac, propylene glycol (E1520), iron oxide black (E172) and potassium hydroxide.
Lenalidomida Stada 15 mg hard capsules EFG:
-Fill of the capsules: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-Capsule coating: iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), titanium dioxide (E171) and gelatin.
-Printing ink: shellac, propylene glycol (E1520), iron oxide black (E172) and potassium hydroxide.
Lenalidomida Stada 20 mg hard capsules EFG:
-Fill of the capsules: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-Capsule coating: iron oxide red (E172), iron oxide yellow (E172), iron oxide black (E172), titanium dioxide (E171) and gelatin.
-Printing ink: shellac, propylene glycol (E1520), iron oxide black (E172) and potassium hydroxide.
Lenalidomida Stada 25 mg hard capsules EFG:
-Fill of the capsules: lactose (see section 2), microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-Capsule coating: titanium dioxide (E171) and gelatin.
-Printing ink: shellac, propylene glycol (E1520), iron oxide black (E172) and potassium hydroxide.
Appearance of the product and contents of the pack
The hard capsules ofLenalidomida Stada5 mg have a green opaque cap and a light brown opaque body, size number 2, 18-19 mm, with the inscription “LP” in black ink on the cap and “638” on the body.
The hard capsules ofLenalidomida Stada10 mg have a yellow opaque cap and a grey opaque body, size number 0, 21-22 mm, with the inscription “LP” in black ink on the cap and “639” on the body.
The hard capsules ofLenalidomida Stada15 mg have a brown opaque cap and a grey opaque body, size number 2, 18-19 mm, with the inscription “LP” in black ink on the cap and “640” on the body.
The hard capsules ofLenalidomida Stada20 mg have a dark red opaque cap and a light grey opaque body, size number 1, 19-20 mm, with the inscription “LP” in black ink on the cap and “641” on the body.
The hard capsules ofLenalidomida Stada25 mg have a white opaque cap and a white opaque body, size number 0, 21-22 mm, with the inscription “LP” in black ink on the cap and “642” on the body.
It is presented in carton containers containing PVC/PCTFE/aluminium foil blisters with 7 capsules in each blister.
Container sizes of 7 or 21 capsules. Only some container sizes may be marketed.
Or
It is presented in carton containers containing perforated and single-dose PVC/PCTFE/aluminium foil blisters with 7x1 capsules in each blister.
Container sizes of 7x1 or 21x1 capsules. Only some container sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder
STADA Laboratorios, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer responsible
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park,
Paola PLA 3000
Malta
or
AdalvoLtd
Malta Life Sciences Park,
Building 1, Level 4,
Sir Temi Zammit Buildings
San GwannIndustrial Estate,
San Gwann SGN 3000,
Malta
or
STADA Arzneimittel AG
Stadastrasse 2 – 18
61118 Bad Vilbel
Germany
or
STADA Arzneimittel GmbH
Muthgasse 36/2
1190 Wien
Austria
Last revision date of this leaflet:June 2024
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS):http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.